
For a phase I clinical trial, the results are the Holy Grail. Yet researchers from the University of Louisville and Brigham and Women's Hospital today reported just such almost-never-attained data.
It marked sustained improvement in all patients with zero adverse effects.
In a Late-Breaking Clinical Trial session at the American Heart Association Scientific Sessions 2012 meeting, Roberto Bolli, M.D., of the University of Louisville and Piero Anversa, M.D., of Brigham and Women's Hospital, Boston, presented data from their groundbreaking research in the use of autologous adult stem cells with patients who had previous heart attacks.
Source: Eurekalert